Zobrazit v EDS

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

Uloženo v:
Podrobná bibliografie
Název: Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients
Autoři: Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Zack Scott, Jenna Elder, Stephen T. Sonis, Richard Straube, Oreola Donini
Zdroj: Biotechnology Reports, Vol 15, Iss C, Pp 24-26 (2017)
Informace o vydavateli: Elsevier, 2017.
Rok vydání: 2017
Sbírka: LCC:Biotechnology
Témata: Innate, Immune, Oral mucositis, Head and neck cancer, Cancer supportive care, Dusquetide, Biotechnology, TP248.13-248.65
Popis: Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.
Druh dokumentu: article
Popis souboru: electronic resource
Jazyk: English
ISSN: 2215-017X
Relation: http://www.sciencedirect.com/science/article/pii/S2215017X17300693; https://doaj.org/toc/2215-017X
DOI: 10.1016/j.btre.2017.05.002
Přístupová URL adresa: https://doaj.org/article/fddb9e034a23439291092f64baaef22f
Přístupové číslo: edsdoj.fddb9e034a23439291092f64baaef22f
Databáze: Directory of Open Access Journals
Popis
Abstrakt:Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.
ISSN:2215017X
DOI:10.1016/j.btre.2017.05.002